AAM
GBT

Aberdeen Asset Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Aberdeen Asset Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$608K Buy
+22,237
New +$662K ﹤0.01% 708
2017
Q1 		– Sell
-46,293
Closed -$669K – 762
2016
Q4 		$669K Buy
+46,293
New +$813K ﹤0.01% 678

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Aberdeen Asset Management's GBT Position: Q2 2017 in Review

Aberdeen Asset Management opened a new position in Global Blood Therapeutics, Inc. (GBT) in Q2 2017: 22,237 shares worth $608K. The stake represents ﹤0.01% of the portfolio and ranks #708 among its holdings. This is a return to the name: Aberdeen Asset Management previously reported a position in GBT as recently as Q4 2016.

Aberdeen Asset Management first reported a position in GBT in Q4 2016 and has held it in 2 quarters since. The position peaked at $669K in Q4 2016. 134 funds tracked by Wall St. Rank hold GBT as of Q2 2017.

  • Aberdeen Asset Management held 22,237 shares of Global Blood Therapeutics, Inc. worth $608K as of Q2 2017.
  • Global Blood Therapeutics, Inc. was a new Aberdeen Asset Management position in Q2 2017.
  • Global Blood Therapeutics, Inc. made up ﹤0.01% of Aberdeen Asset Management's portfolio in Q2 2017, its #708 holding.
  • Aberdeen Asset Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2016 and has held it in 2 quarters since.
  • Aberdeen Asset Management's Global Blood Therapeutics, Inc. position peaked at $669K in Q4 2016.
  • 134 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2017.

Based on Aberdeen Asset Management's 13F filing for Q2 2017, filed 10 Aug 2017.